Pfizer vax 'minimal risk' for patients with Guillain-Barre history
Real-world data from Israel suggest recurrence of the syndrome is rare
Patients with a history of Guillain-Barré syndrome appear to have a low risk of recurrence if they are vaccinated with Comirnaty, a study of medical records shows.
Doctors from Maccabi Healthcare Services in Tel Aviv, which serves a quarter of the Israeli population, have reported outcomes for 579 patients with a history of Guillain-Barré syndrome (GBS) who subsequently received the mRNA COVID-19 vaccine as guidelines did not contraindicate it.
In total, 539 of
